Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FGFR2 H167_N173del FGFR2 L618F||intrahepatic cholangiocarcinoma||predicted - resistant||Debio 1347||Case Reports/Case Series||Actionable||In a Phase I trial, an intrahepatic cholangioncarcinoma patient who progressed in Debio 1347 was found to have acquired FGFR2 L618F, and co-expression of FGFR2 H167_N173del and FGFR2 L618F an intrahepatic cholangiocarcinoma cell line led to a reduced response to Debio 1347 treatment compared to cells expressing wild-type FGFR2 in culture (PMID: 33926920).||33926920|
|FGFR2 H167_N173del FGFR2 L618F||intrahepatic cholangiocarcinoma||predicted - sensitive||Futibatinib||Case Reports/Case Series||Actionable||In a Phase I trial, Futibatinib (TAS-120) treatment led to a partial response with 61% tumor reduction and response duration of 17 months in an intrahepatic cholangiocarcinoma patient harboring FGFR2 H167_N173del and FGFR2 L618F, which was consistent with inhibition of growth in an intrahepatic cholangiocarcinoma cell line expressing FGFR2 H167_N173del and FGFR2 L618F in culture (PMID: 33926920).||33926920|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|